19-50417153-C-T

Position:

• chr19-50417153-C-T

Variant summary

Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_Strong BP6_Very_Strong BA1

The NM_002691.4(POLD1):​c.3121-19C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0211 in 1,580,788 control chromosomes in the GnomAD database, including 3,586 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★). There are indicators that this mutation may affect the branch point..

• Frequency:
  • Genomes: 𝑓 0.088 (1883 hom., cov: 34)
  • Exomes 𝑓: 0.014 (1703 hom.)
• Consequence: POLD1 NM_002691.4 intron
• Clinical Significance: Benign criteria provided, multiple submitters, no conflicts B:10
• Conservation: PhyloP100: -0.329

Genes affected

POLD1 (HGNC:9175): (DNA polymerase delta 1, catalytic subunit) This gene encodes the 125-kDa catalytic subunit of DNA polymerase delta. DNA polymerase delta possesses both polymerase and 3' to 5' exonuclease activity and plays a critical role in DNA replication and repair. Alternatively spliced transcript variants have been observed for this gene, and a pseudogene of this gene is located on the long arm of chromosome 6. [provided by RefSeq, Mar 2012]

ENSG00000142539 (HGNC:):

ACMG classification

Verdict is Benign. Variant got -20 ACMG points.

• BP4: This place is a probable branch point but likely benign (scored 3 / 10). Computational evidence support a benign effect (BayesDel_noAF=-0.86).
• BP6: Variant 19-50417153-C-T is Benign according to our data. Variant chr19-50417153-C-T is described in ClinVar as [Benign]. Clinvar id is 380229.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr19-50417153-C-T is described in Lovd as [Benign].
• BA1: GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.285 is higher than 0.05.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	MANE	Protein	UniProt
POLD1	NM_002691.4	c.3121-19C>T		intron_variant		ENST00000440232.7	NP_002682.2

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	TSL	MANE	Protein	Appris	UniProt
POLD1	ENST00000440232.7	c.3121-19C>T		intron_variant		1	NM_002691.4	ENSP00000406046.1
ENSG00000142539	ENST00000599632.1	c.328-19C>T		intron_variant		5		ENSP00000473233.1

Frequencies

GnomAD3 genomes AF: 0.0881 AC: 13392 AN: 152034 Hom.: 1871 Cov.: 34

Gnomad AFR AF: 0.289

Gnomad AMI AF: 0.00

Gnomad AMR AF: 0.0426

Gnomad ASJ AF: 0.0274

Gnomad EAS AF: 0.00135

Gnomad SAS AF: 0.0530

Gnomad FIN AF: 0.00

Gnomad MID AF: 0.0570

Gnomad NFE AF: 0.00403

Gnomad OTH AF: 0.0693

GnomAD3 exomes AF: 0.0307 AC: 6040 AN: 197046 Hom.: 569 AF XY: 0.0269 AC XY: 2866 AN XY: 106722

Gnomad AFR exome AF: 0.304

Gnomad AMR exome AF: 0.0193

Gnomad ASJ exome AF: 0.0236

Gnomad EAS exome AF: 0.000810

Gnomad SAS exome AF: 0.0473

Gnomad FIN exome AF: 0.0000611

Gnomad NFE exome AF: 0.00407

Gnomad OTH exome AF: 0.0220

GnomAD4 exome AF: 0.0140 AC: 19934 AN: 1428636 Hom.: 1703 Cov.: 33 AF XY: 0.0141 AC XY: 9954 AN XY: 708196

Gnomad4 AFR exome AF: 0.297

Gnomad4 AMR exome AF: 0.0212

Gnomad4 ASJ exome AF: 0.0247

Gnomad4 EAS exome AF: 0.000688

Gnomad4 SAS exome AF: 0.0469

Gnomad4 FIN exome AF: 0.0000604

Gnomad4 NFE exome AF: 0.00278

Gnomad4 OTH exome AF: 0.0277

GnomAD4 genome AF: 0.0884 AC: 13450 AN: 152152 Hom.: 1883 Cov.: 34 AF XY: 0.0866 AC XY: 6444 AN XY: 74408

Gnomad4 AFR AF: 0.289

Gnomad4 AMR AF: 0.0424

Gnomad4 ASJ AF: 0.0274

Gnomad4 EAS AF: 0.00135

Gnomad4 SAS AF: 0.0533

Gnomad4 FIN AF: 0.00

Gnomad4 NFE AF: 0.00403

Gnomad4 OTH AF: 0.0733

Alfa AF: 0.0151 Hom.: 32

Bravo AF: 0.0990

Asia WGS AF: 0.0680 AC: 238 AN: 3478

ClinVar

Significance: Benign

Submissions summary: Benign:10

Revision: criteria provided, multiple submitters, no conflicts

Submissions by phenotype

not specified Benign:5

Benign, criteria provided, single submitter	clinical testing	PreventionGenetics, part of Exact Sciences	Nov 02, 2016	- -
Benign, no assertion criteria provided	clinical testing	Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)	-	- -
Benign, criteria provided, single submitter	clinical testing	GeneDx	Nov 06, 2015	This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
Benign, no assertion criteria provided	clinical testing	Clinical Genetics, Academic Medical Center	-	- -
Benign, criteria provided, single submitter	clinical testing	Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital	Aug 15, 2023	- -

not provided Benign:2

Benign, criteria provided, single submitter	clinical testing	Women's Health and Genetics/Laboratory Corporation of America, LabCorp	May 16, 2016	Variant summary: The POLD1 c.3121-19C>T variant involves the alteration of a non-conserved intronic nucleotide. One in silico tool predicts a benign outcome for this variant. 4/5 splice prediction tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. This variant was found in 2587/33868 control chromosomes (272 homozygotes) at a frequency of 0.0763848, which is approximately 5377 times the estimated maximal expected allele frequency of a pathogenic POLD1 variant (0.0000142), suggesting this variant is likely a benign polymorphism. Taken together, this variant is classified as benign. -
Benign, criteria provided, single submitter	not provided	Breakthrough Genomics, Breakthrough Genomics	-	- -

Colorectal cancer, susceptibility to, 10 Benign:2

Benign, criteria provided, single submitter	clinical testing	Labcorp Genetics (formerly Invitae), Labcorp	Feb 01, 2024	- -
Benign, criteria provided, single submitter	clinical testing	KCCC/NGS Laboratory, Kuwait Cancer Control Center	Jul 07, 2023	- -

Hereditary cancer-predisposing syndrome Benign:1

Benign, criteria provided, single submitter

clinical testing

Ambry Genetics

May 21, 2015

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
BayesDel_noAF	Benign	-0.86
CADD	Benign	2.6
DANN	Benign	0.92
BranchPoint Hunter		3.0
RBP_binding_hub_radar		1.0
RBP_regulation_power_radar		2.3

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.030		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs3212330; hg19: chr19-50920410;